Comienza el contenido principal

I Simposio iLUNG: oncología traslacional y nanotecnología para la medicina personalizada en cáncer de pulmón

Ciencias de la Vida y de la Materia Simposio Martes, 24 de septiembre de 2024, 09:30 horas Madrid

Información general:

Sede: Fundación Ramón Areces - salón de actos. Calle Vitruvio, 5. 28006. Madrid.

Asistencia gratuita hasta completar aforo. Necesaria inscripción online previa. El simposio se desarrollará en inglés.

Organizado por:

Fundación Ramón Areces y ILUNG 2.0

En colaboración con:

Fundación Oncosur

Moderador/es:

Luis Paz-Ares-Head of Medical Oncology at Hospital 12 de Octubre, group leader of the H12O-CNIO Lung Cancer Unit (CNIO) and the Thoracic Oncology Lab (Imas12) and Professor of Medicine (Complutense University).

Audios

I Simposio iLUNG: cáncer de pulmón

Ver más contenido multimedia de esta actividad

Descripción
Programa
Ponente/s

l cáncer de pulmón destaca entre los tumores más frecuentes y de peor pronóstico en las sociedades avanzadas. Dado que el cáncer de pulmón a veces depende de oncogenes que pueden ser vulnerables, en la última década se han incorporado a los tratamientos estándar una serie de terapias dirigidas a alteraciones genéticas específicas. Así, el cáncer de pulmón se ha convertido en un paradigma de la medicina personalizada.

A pesar de estos avances recientes en biología molecular, nuestra comprensión sobre las vulnerabilidades de las células tumorales que pueden ser explotadas terapéuticamente, los cambios celulares que conducen a la aparición de cáncer de pulmón y a su resistencia a la terapia, es aún limitada.

El programa científico iLUNG 2.0, financiado por la Comunidad Autónoma de Madrid, pretende combinar la física y la biología celular al servicio de la investigación preclínica y clínica para avanzar tanto en la comprensión como en las oportunidades terapéuticas, y desarrollar nuevas estrategias personalizadas para el tratamiento de esta enfermedad.

Con este simposio, los cinco grupos integrantes del iLUNG 2.0, liderados cada uno por Luis Paz-Ares (UCM), Fernando López-Ríos (H12O), Marcos Malumbres (CNIO), Mariano Barbacid (CNIO) y Javier Tamayo (CSIC), quieren dedicar un día para discutir enfoques multidisciplinarios en el ámbito de la medicina personalizada del cáncer de pulmón, con la contribución de sus componentes y de científicos internacionales especializados en la materia.

El evento quiere ser un espacio para la creación de redes científicas proactivas en un entorno informal y está abierto a personas interesadas en oncología y nanotecnología traslacional en cáncer de pulmón, división celular y cáncer, oncología experimental y dianas terapéuticas.

"La Fundación Ramón Areces no se hace responsable de las opiniones, comentarios o manifestaciones realizadas por las personas que participan en sus actividades".

Martes, 24 de septiembre

09:00 h.

Registro de asistentes

09:15 h.

Bienvenida

Mariano Barbacid
CNIO, Madrid.

09:30 h.

Apertura del evento

Luis Paz-Ares
UCM - Hospital 12 de Octubre, Madrid.

09:45 h.

Clinically applied spatial trascriptomics in lung cancer

Jon Zugazagoitia
Hospital 12 de Octubre, Madrid.

10:15 h.

Artificial intelligence for lung cancer: complementing targeted therapies and immunotherapy

Fernando López-Ríos
Hospital 12 de Octubre, Madrid.

10:45 h.

Investigating the interplay between KRAS oncogenic signaling and tumour immune evasion in lung

Julian Downward
Francis Crick Institute, Londres.

11:45 h.

Pausa

12:15 h.

Opportunities for cell-cycle-targeted therapies in Lung cancer

Marcos Malumbres
CNIO, Madrid - VHIO, Barcelona.

12:45 h.

Targeting KRAS driven cancers

Mónica Musteanu
Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid.

13:15 h.

Exploring Cancer Cells through the Lens of Physics: The Role of Optomechanical Tecnologies

Javier Tamayo
Instituto Nacional de Materiales, CSIC, Madrid.

13:45 h.

Iron import and immune suppression in squamous lung carcinoma

Álvaro Ucero
UCM - Hospital 12 de Octubre, Madrid.

14:15 h.

Pausa

15:30 h.

Presentaciones orales

17:00 h.

Fin del simposio

Jon Zugazogoitia

Department of Medical Oncology, Thoracic Cancer and Early Phase I Unit,Tumor Microenvironment and Immunotherapy Research Group.

12 de Octubre Hospital and i+12 Research Institute. Madrid, Spain.

I am a physician-scientist focused in lung cancer. Faculty member and independent investigator at the 12 de Octubre Hospital. Principal investigator of the Tumor Microenvironment and Immunotherapy Research Group. My research interests are focused on discovery of biomarkers and mechanisms of sensitivity and resistance to immunotherapy and targeted therapies for patients with lung cancer.

Julian Downward

(Associate Research Director at the Francis Crick Institute and Senior Group Leader at the Institute of Cancer Research., London)

Professor Julian Downward earned his bachelor’s degree in Natural Sciences from the University of Cambridge and completed his PhD in Michael Waterfield's lab at the Imperial Cancer Research Fund Laboratories in London. In 1984, during his PhD, he linked a retroviral oncogene (v-erbB) to a cellular growth regulatory protein, EGFR.

In 1986, he joined Robert Weinberg’s lab at the Whitehead Institute, Massachusetts Institute of Technology in Cambridge, US, to study RAS proteins in human cancer. In 1989, he founded his lab at the Imperial Cancer Research Fund, later the Cancer Research UK London Research Institute. His group explored the molecular mechanisms and regulation of oncogenic RAS proteins and their mutational activation in tumors. This lab moved to the Francis Crick Institute in St. Pancras in early 2016. Since 2012, he has also led a small group at the ICR, focusing on translating his lung cancer research into clinical practice.

In 2005, Professor Downward became a Fellow of the Royal Society, the UK’s national academy of sciences, and Associate Director of the Cancer Research UK London Research Institute, later serving as Associate Research Director of the Francis Crick Institute. He is also a Fellow of the Academy of Medical Sciences, a Member of the European Molecular Biology Organisation, and an honorary Fellow of the Royal College of Physicians. Research in Professor Downward’s lab at the ICR is funded by a Senior Investigator Award from the Wellcome Trust.

Mariano Barbacid

(Experimental Oncology Lab, Spanish National Cancer Research Center, Madrid)

Mariano Barbacid earned his Ph.D. from Madrid’s Universidad Complutense in 1974 and conducted postdoctoral research at the US National Cancer Institute until 1978. He established his research group to investigate molecular events in human tumor development, leading to the isolation of the first human oncogene in 1982. Barbacid's work elucidated the connection between Ras oncogenes and chemical carcinogens, laying the groundwork for epidemiological studies on cancer causation. His discovery of the TRK oncogene facilitated the development of tumor-agnostic therapies by biotech companies. Barbacid later joined Bristol Myers-Squibb, pioneering targeted therapies. In 1998, he founded and directed the Spanish National Cancer Research Center (CNIO), a leading global cancer research institution.

Transitioning to cell cycle regulation research, Barbacid's work redefined CDKs' role in mammalian cell cycles. He resumed focus on K-RAS mutant tumors, exploring therapeutic strategies using genetically engineered mouse models. Barbacid’s accolades include induction into the US National Academy of Sciences and Fellowship in the American Association for Cancer Research. He received numerous awards and honors for his contributions to cancer research, including prestigious international prizes and grants. With over 300 publications, Barbacid remains a prominent figure in cancer research with significant impact in the field.

Javier Tamayo

Bionanomechanics Lab. Micro and Nanotechnology Institute. CSIC, Madrid)

Dr. Javier Tamayo obtained his PhD in Physics in 1998 and was a postdoctoral Marie Curie fellow at the University of Bristol (UK). He is a Full Professor at CSIC and received the RSEF award in “Física, Innovación y Tecnología” in 2018. His research focuses on nanomechanics and optomechanics for ultrasensitive molecular detection and cellular mechanobiology, with over 98 articles, more than 7700 citations, and an h-index of 45.

Dr. Tamayo has developed concepts bridging physics and biology, including identifying biophysical markers for cancer mechanobiology and detecting pathogens He created a hybrid opto-mechano-plasmonic biosensor for detecting tumor biomarkers at 100 ag/mL, exceeding existing. This technology was used in clinical trials with cancer patient samples, funded by the Spanish Association Against Cancer (2016-2019). He has coordinated a FET-Proactive-RIA project (2016-2022) with over 7 million euros in funding. Dr. Tamayo has transferred technologies to industry with eight licensed patents. He founded spin-off companies Mecwins S.A., Sensia S.L., and Nanodreams S.L., and licensed innovations to Infinitesima Ltd. Mecwins' nanosensors, based on his research, were co-developed with Quidel (USA). He leads the Bionanomechanics group at CSIC.

Álvaro Ucero

(Physiology Department at Medical School. Complutense University of Madrid)

His research career has focused on understanding the pathophysiology of tissue fibrosis and cancer. He has investigated the effect of modulating inflammatory pathways on fibroblasts and on kidney and lung fibrosis, by using pharmacologic approaches (chemicals, nanoparticles), genetically engineered mouse models or even laser therapies. His research has also found disease biomarkers like osteoprotegerin in urine exosomes for human kidney damage, or the transcription factor AP-1/Fra-2 and the type VI collagen in lung fibrosis. He found that both Fra-2 and its transcriptional target, Type VI collagen, play a central role in type 2 immunity induced lung fibrosis. In Boston (Kalluri´s Lab, BIDMC) and Madrid (Wagner´s Lab, CNIO) Dr. Ucero got interested in the cancer field, in particular, in the cell crosstalk within a tumor, and in the cellular and molecular similarities with tissue fibrosis. In 2021, he incorporated as an Assistant Professor of Physiology at the School of Medicine in the Universidad Complutense de Madrid (UCM) and as a group leader of the "Intercellular Crosstalk in Aging & Cancer" lab at Imas12 Institute (Madrid). His group tries to find relevant events in the communication between tumor cells and stromal cells that can represent predictive biomarkers and novel therapeutic targets in lung cancers.

Marcos Malumbres

(ICREA Professor: System Oncology Program Director and Cancer Cell Cycle group leader at Vall d’Hebron Institute of Oncology (VHIO). Barcelona & Spanish National Cancer Research Centre (CNIO))

Research at Malumbres’ lab is oriented towards scientific questions of relevance for understanding and treating several cancer types including breast, ovarian, endometrial, pancreatic or lung cancer among others. His group has studied mechanisms of cell cycle control and implications in cancer therapy for more than 20 years, including functional relevance and therapeutic value of CDK4/6 inhibitors. Main interests in the group include understanding tumor evolution and response to treatments by using single-cell studies in circulating tumors cells and new therapeutic targets for untreatable tumors. He is a visiting professor at the Dana Farber Cancer Center (DFCI, Harvard University, Boston) and was elected EMBO member in 2016.

Fernando López - Ríos

(Instituto de Investigación Biomédica Hospital 12 de Octubre)

Fernando Lopez-Rios is the Chief of the Molecular Diagnostics Service at Hospital Universitario 12 de Octubre (Madrid) and Professor of Pathology at Universidad Complutense (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” (Spain) and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is the 2023 recipient of the Mary J. Matthews Pathology & Transitional Research Award and the Deputy Chair of the IASLC Pathology Committee.

Luis Paz-Ares

(Head of Medical Oncology at Hospital 12 de Octubre, group leader of the H12O-CNIO Lung Cancer Unit (CNIO) and the Thoracic Oncology Lab (Imas12) and Professor of Medicine (Complutense University).)

Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center). He is also member of the board of CiberONC (National Network of Cancer Research), and active member of Cooperative Groups (EORTC, ETOP; SLCG, SOGUG) and Scientific Societies (ASCO, ESMO, IASLC, SEOM, ASEICA).

He graduated with a degree in Medicine from the Universidad Autonoma de Madrid, in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993- 1995) and he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014). Luis Paz-Ares's research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 414 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology,etc. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He got several research awards like the Fundación Lilly and Ramiro Carregal in 2017.

Mónica Musteanu

Her research career started at the Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria, where she completed her PhD thesis focusing on the study of the role of Stat3 in intestinal tumourigenesis and the development of a new genetically modified mouse model to test the cooperativity between signalling pathways in tumour development. Monica received her PhD from the Medical University of Vienna in November 2009.

In 2010, Monica was awarded the CNIO-Caja Navarra postdoctoral fellowship and moved to Madrid to work in the laboratory of Dr. Manuel Hidalgo in the Clinical Research Programme at the Spanish National Cancer Research Centre (CNIO), focusing her research on translational studies in pancreatic and lung cancer in close collaboration with medical staff and the pharmaceutical industry.

During 2013 - 2020 as Staff Scientist in Dr. Mariano Barbacid's group at the CNIO she focused on identifying therapeutic strategies for KRAS-driven mutant lung adenocarcinoma, deciphering the role of RAF1 in KRAS-driven lung cancer progression. In addition, Monica established and ran a ‘Mouse Clinic’ of genetically modified mouse models for lung adenocarcinoma as a platform for cancer drug development in collaboration with and funded by pharmaceutical companies to test new drugs in KRAS-mutated lung adenocarcinomas.

In 2020 Mónica was awarded the ‘Ramón y Cajal’ grant from the Spanish Ministry of Science, Innovation and Universities and started her new position as professor and group leader in the Department of Biochemistry and Molecular Biology at the Complutense University of Madrid.She focuses her research on the identification of new target genes and pharmacological compounds capable of restoring interferon signalling and reversing the immunosuppressive phenotype of KRAS-mutated lung tumours.